Your browser doesn't support javascript.
loading
Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma.
Korani, Mitra; Ghaffari, Solmaz; Attar, Hossein; Mashreghi, Mohammad; Jaafari, Mahmoud Reza.
Afiliación
  • Korani M; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ghaffari S; Department of Pharmaceutics, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Young Researchers and Elite Club, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Attar H; Chemical Engineering Department, Engineering and Technology Faculty, Sciences and Research Branch, Islamic Azad University, Tehran, Iran.
  • Mashreghi M; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Jaafari MR; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: Jafarimr@mums.ac.ir.
Nanomedicine ; 20: 102013, 2019 08.
Article en En | MEDLINE | ID: mdl-31103736
Three Bortezomib (BTZ) liposomal formulations including of HSPC/Cholesterol/DSPE-mPEG2000 (F1), HSPC/DSPG/Cholesterol (F2), and HSPC/DSPG/Cholesterol/DSPE-mPEG2000 (F3) were prepared and characterized. Results demonstrated that the size of formulations ranged 72-92 nm. The DSPE-mPEG2000 containing formulations (F1 and F3) had higher BTZ encapsulation compared to F2 formulation. The size of the liposomal formulations increased slightly when stored at 4 °C for 6 months; the zeta potential of formulations remained constant. There were no significant differences in the release properties BTZ from liposomal formulations in pH 7.0; however, in acidic pH of 5.5 the release of BTZ from F1 and F3 was higher than F2. Three formulations cytotoxicity studies demonstrated IC50 values more than free BTZ on all cell lines examined. Evaluation of antitumor activity in mice bearing C26 colon carcinoma and B16F0 melanoma tumors showed that all the designed liposomal formulations have higher efficacy compared to free BTZ. In tumor models, F2 was more effective than the F1 and F3. Our findings indicated that F2 considerably increased the therapeutic efficacy of BTZ, which promises new formulation with the potential use in clinic and merits further investigation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Melanoma Experimental / Neoplasias del Colon / Nanopartículas / Bortezomib / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Melanoma Experimental / Neoplasias del Colon / Nanopartículas / Bortezomib / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos